Testicular Cancer | NYU Langone Health
Perlmutter Cancer Center urologists, surgeons, and oncologists work together to diagnose and treat testicular cancer.
Testing Offered at the Voice Center | NYU Langone Health
At NYU Langone’s Voice Center, we offer a range of specialized tests for voice, swallowing, and airway conditions.
Tests for Infertility | NYU Langone Health
At the NYU Langone Fertility Center, experts can perform a variety of tests to assess your fertility potential.
Tetralogy of Fallot in Children | NYU Langone Health
Doctors at the Pediatric Congenital Heart Program at Hassenfeld Children’s Hospital at NYU Langone treat children who have tetralogy of Fallot.
TH-189: A Phase 2 Study of Nivolumab plus Ramucirumab in Patients with Recurrent Advanced Metastatic Non-Small Cell Lung Carcinoma
The study will enroll patients with prior IO therapy (alone or in combination withchemotherapy or in combination with other IO agents) regardless of the PD-L1 level, into anon-randomized combination trial, with primary endpoint of disease control rate (see Schema).At Fox Chase Cancer Center, we see roughly 10,000 new patients annually, and enrollapproximately 700 patients annually on clinical trials, including at least 60 lung cancerpatients. This is a multi-center trial with expected 2-3 participating centers. We intend to enroll39 IO-experienced patients within 8 months (4-5 patients per month).The study will also utilize a Simon’s optimal two-stage design, and the accrual will beterminated early due to futility based upon 19 patients as described in the statisticalconsideration in section 12.2. Up to 39 evaluable patients will be accrued to this trial.
The (IRAD) International Registry for Acute Aortic Dissection
The purpose of this study is to collect information regarding your medical condition for a registry. The aim of the registry is to document a few important medical details of patients like you who were hospitalized for an acute aortic dissection. An aortic dissection is a serious condition in which a tear occurs in the inner layer of the body's main artery (aorta). Blood rushes through the tear, causing the inner and middle layers of the aorta to split (dissect). Based on the rarity of this disease and few guidelines regarding the most effective treatment for this disease, this registry aims to collect information from patients like you to study this disease. Patients from various hospitals in this country and in several other countries are being asked to participate. This information will help doctors understand more about acute aortic dissection. We believe this information will help to improve the treatment of patients like you in the future.
The ConsideRAte study. A multipart exploratory study to evaluate splenic nerve stimulation in patients with rheumatoid arthritis.
The ConsideRAte study This study will evaluate the safety, tolerability, and effects ofstimulating the splenic neurovascular bundle (NVB) with an activeimplantable medical device system. The study will consist of 4 studyperiods, including a Randomized Control Trial period (Period 1), anOpen Label period (Period 2), a Treat-to-target period (Period 3), and aLong-term Follow-up period (Period 4). Participants with activerheumatoid arthritis (RA) will receive an implantable system and,following a recovery period of at least 28 days after implant of thesystem, will be randomly assigned at Day 1 (of Period 1) to receiveeither active stimulation or sham-stimulation via this system for 12weeks (84 days). Day 1 assessments will be used as baseline.Summary of IB Version 2:Version 1, 16 Dec 2020 Initial ReleaseVersion 2, 23 Jul 2021 Add preclinical testing supporting increase target stimulation dose increase from 15 mA to 20 mACover Page, Headers, Table of Contents Updated version, DatePage 3 Updated Sponsor signatory to Chief Medical OfficerSection 2.4 Removed previous target amplitudeSection 2.7 Added brief description of preclinical study (2nd GLP study); brief conclusionsSection 6.1 Added mention of new GLP study and brief resultsFigure 20 Corrected max dose amplitude in from 15 mA to 20 mASection 9.2 Added brief description of the new preclinical study (GAL1063)Section 9.4 Added more detailed description and results of the new preclinical study (GAL1063)Table numbers and section numbers Adjusted tables numbers and section numbers to account for the section added to describe the new GLP studySection 13.1.5 Updated results and figures from the new GLP study (GAL1063)Section 13.5.2 Updated estimated nerve recruitment rates and figure at the new target amplitude (20 mA) Section 14 Appendix II Added background rationale for GAL1063 study. Change to IB Version 3: Version 1, 16 Dec 2020 Initial ReleaseVersion 2, 23 Jul 2021 Add preclinical testing supporting increase target stimulation dose increase from 15 mA to 20 mACover Page, Headers, Table of Contents Updated version, DatePage 3 Updated Sponsor signatory to Chief Medical OfficerSection 2.4 Removed previous target amplitudeSection 2.7 Added brief description of preclinical study (2nd GLP study); brief conclusionsSection 6.1 Added mention of new GLP study and brief resultsFigure 20 Corrected max dose amplitude in from 15 mA to 20 mASection 9.2 Added brief description of the new preclinical study (GAL1063)Section 9.4 Added more detailed description and results of the new preclinical study (GAL1063)Table numbers and section numbers Adjusted tables numbers and section numbers to account for the section added to describe the new GLP studySection 13.1.5 Updated results and figures from the new GLP study (GAL1063)Section 13.5.2 Updated estimated nerve recruitment rates and figure at the new target amplitude (20 mA) Section 14 Appendix II Added background rationale for GAL1063 study. Version 3; 22 Oct 2021 Revised to include new validation packaging results, and updated tables from V&V testingCover Page, Headers, Table of Contents Updated version, DateSection 11.1 Updated Table 14 to describe the correction for Failed package testing as complete. Updated Table 15 & 16 to describe the design changes for the packages that were re-tested, and results.Section 11.1.1 Updated Table 18 V&V testing table to include the GAL1063 GLP study and PASS criteria
The DISCOVER INOCA Prospective Multi-center Registry - Determining the Cause of Coronary Vasomotor Disorders in Patients with Ischemia and No Obstructive Coronary Artery Disease
This is a prospective, multicenter, registry of stable patients with ischemia and no obstructive coronary artery disease (INOCA) evaluated by coronary angiography, intravascular imaging, and physiologic measurements obtained on the Coroventis Coroflow Cardiovascular System.The Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire (Abbott, Abbott Park, IL) are a device combination consisting of a physiology wire with wireless transmitter (Wi-Box), CoroHub Receiver, and CoroFlow Software. The PressureWire™ X guidewire is a hydrophilic-coated wire with pressure and temperature sensors that is capable of measuring physiologic indices including fractional flow reserve (FFR), resting full cycle ratio (RFR), coronary flow reserve (CFR), and the index of microcirculatory resistance (IMR). The guidewire wirelessly transmits pressure and temperature data via the Wi-Box to the CoroHub Receiver and CoroFlow Software, which is a software interface designed to display pressure measurements, thermodilution curves, and physiologic indices. This registry will enroll 500 subjects at up to 10 sites in the United States that use the Abbott Coroventis Coroflow Cardiovascular System.The overall objective of this multi-center registry is to identify specific phenotypes of INOCA with both an anatomic evaluation (coronary angiography and intravascular imaging) and physiologic assessment with the Abbott Coroventis Coroflow Cardiovascular System, and to determine long-term outcomes. Specific goals include:- Describe the prevalence of the following INOCA phenotypes: coronary microvascular dysfunction (CMD), vasospastic angina, mixed CMD/vasospastic angina, other disorders of coronary physiology, and non-cardiac chest pain;- Characterize the burden of epicardial coronary artery atherosclerosis and myocardial bridging (MB) by angiography and intracoronary imaging (intravascular ultrasound or optical coherence tomography) in patients with INOCA;- Characterize the natural history and outcomes of patients with INOCA and determine variables associated with major adverse cardiovascular events
The Effect of Bone-void filler on Anterior Knee Pain Following ACL Reconstruction with Bone-Patellar Tendon Bone Autograft
This study will compare 3 commonly used bone-void fillers, autologous bone, calcium phosphate cement, and demineralized bone matrix to fill the bony defect association with harvesting the patellar tendon autograft for ACL reconstruction.
The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis
This is a randomised, multicentre, double-blinded, parallel-group trial comparing semaglutide s.c. 2.4 mg once-weekly versus placebo in subjects with NASH and fibrosis stage 2 or 3. The trial has two parts, a part 1 and a part 2, with distinctive objectives and endpoints.Part 1 of the trial: To demonstrate that treatment with semaglutide s.c. 2.4 mg improves liver histology compared to placebo in subjects with NASH and fibrosis stage 2 or 3.Part 2 of the trial: To demonstrate that treatment with semaglutide s.c. 2.4 mg lowers the risk of liver-related clinical events compared to placebo in subjects with NASH and fibrosis stage 2 or 3.